Transcode Therapeutics, Inc. Annual Performance Review

Transcode Therapeutics is a clinical-stage company focused on cancer research. They use a proprietary nanoparticle platform to create RNA-based treatments. Their lead drug, TTX-MC138, is currently in a Phase 0/1 clinical trial for solid tumors. As a research-focused entity, Transcode is currently building its pipeline, including TTX-siRNA and TTX-miRNA candidates, while integrating new assets from their recent expansion into immunotherapy.

Financial Performance

Transcode reported zero revenue for the year ending December 31, 2025, which is typical for a company that has not yet brought a product to market. The company reported a net loss of approximately $18.4 million, driven by $10.2 million in research costs and $8.2 million in administrative expenses. To fund these operations, the company sold additional shares and issued convertible preferred stock. The October 2025 acquisition of ABCJ, LLC (Polynoma) was financed entirely through stock, involving the issuance of Series A, B, and C non-voting convertible preferred stock, which significantly altered the company’s capital structure.

Strategic Wins and Operational Hurdles

• Strategic Expansion: The acquisition of ABCJ, LLC provided Transcode with the clinical-stage immunotherapy drug BRACO-19 and new intellectual property for melanoma treatments. Additionally, a licensing agreement signed in early 2026 with Unleash Immuno Oncolytics further expands their presence in cancer immunotherapy.
• Funding Strategy: The company maintains a Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors, allowing them to sell up to $15 million in common stock as needed. This is a critical lifeline, as the company’s 2025 burn rate averaged approximately $1.5 million per month.
• Shareholder Impact: Reliance on equity financing has led to a significant increase in the number of shares outstanding—growing by over 40% compared to the previous year. This dilution reduces the ownership percentage of existing shareholders.

Financial Health and Sustainability

As of December 31, 2025, Transcode held approximately $4.2 million in cash. Management has issued a "going concern" warning, indicating that current cash reserves are insufficient to fund operations for the next 12 months without additional capital. The company’s capital structure is heavily weighted toward non-voting convertible preferred stock, which holds priority over common stock in the event of a sale or dissolution. While these instruments provide a mechanism for raising capital without immediate loss of voting control, they create a complex financial profile that may impact future fundraising efforts.

Key Risks for Investors

• Dilution: Continued reliance on stock sales to fund operations will likely result in further dilution for existing shareholders.
• Going Concern Status: Auditors have expressed doubt regarding the company’s ability to continue as a going concern. Failure to secure additional funding within six months would likely force a suspension of clinical trials.
• Clinical Concentration: The company’s valuation is tied almost exclusively to the success of TTX-MC138. A failure in trial data would leave the company without a primary revenue-generating asset.
• Nasdaq Compliance: Transcode has faced challenges maintaining a stock price above the $1.00 threshold. Failure to meet Nasdaq equity requirements could lead to delisting, which would significantly impair the company's ability to raise capital.

Future Outlook

The 2026 roadmap centers on three primary objectives: advancing the TTX-MC138 clinical trial, initiating development on BRACO-19, and managing cash flow through strategic stock sales. Management is actively seeking non-dilutive funding, such as government grants or partnerships with larger pharmaceutical entities, to mitigate the need for further share issuance. Long-term stability remains contingent on achieving positive clinical trial results to attract investment and strengthen the balance sheet.

Investor Note: When evaluating this opportunity, consider the balance between the company's clinical potential and its current financial constraints. The "going concern" warning and the reliance on share dilution are significant factors that weigh heavily against the potential upside of their pipeline. Success for investors is tied directly to the company's ability to secure non-dilutive funding or reach a major clinical milestone before their current cash reserves are exhausted.